Anthem Biosciences
Anthem Biosciences, a leading biotechnology firm headquartered in India, has established itself as a key player in the life sciences industry since its inception in 2009. With a strong operational presence across various regions, the company focuses on providing innovative solutions in drug discovery, development, and manufacturing. Specialising in custom biologics, Anthem Biosciences offers a range of services, including monoclonal antibody development and protein expression systems. Their commitment to quality and efficiency sets them apart in a competitive market. Over the years, the company has achieved significant milestones, enhancing its reputation for excellence in biopharmaceutical services. Recognised for its cutting-edge technologies and robust client partnerships, Anthem Biosciences continues to drive advancements in the biotechnology sector, positioning itself as a trusted partner for pharmaceutical and biotech companies worldwide.
DitchCarbon Score
How does Anthem Biosciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Anthem Biosciences's score of 14 is lower than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Anthem Biosciences's reported carbon emissions
In 2023, Anthem Biosciences reported total carbon emissions of approximately 12,650,000 kg CO2e. This figure includes about 10,798,000 kg CO2e from Scope 1 emissions and around 2,355,000 kg CO2e from Scope 2 emissions. The company has shown a significant increase in emissions from the previous year, where total emissions were about 17,631,000 kg CO2e in 2024, with Scope 1 emissions at approximately 13,561,000 kg CO2e and Scope 2 emissions at about 3,923,000 kg CO2e. Anthem Biosciences has committed to near-term climate targets, although specific reduction targets have not been disclosed. The company is not currently committed to a net-zero target. Their operations fall within the Pharmaceuticals, Biotechnology, and Life Sciences sector, and they are based in India. As of January 2024, they have acknowledged their commitment to reducing emissions but have not specified any formal targets or timelines for these reductions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 10,798,000 | 00,000,000 |
| Scope 2 | 2,355,000 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Anthem Biosciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
